Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688507 | 0.96 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EALDH1A1FFAR1ITGB1 | |
| SCHEMBL687688 | 0.96 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EALDH1A1FFAR1PTGER3 | |
| SCHEMBL688501 | 0.96 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EALDH1A1FFAR1PTGER3 | |
| SCHEMBL688946 | 0.95 | SMN1; SMN2 (0.34) | SMN1; SMN2KDM4EALDH1A1FFAR1ITGB1 | |
| SCHEMBL686996 | 0.95 | P2RX3 (0.35) | SMN1; SMN2KDM4EALDH1A1FFAR1ITGB1 | |
| SCHEMBL687119 | 0.95 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EALDH1A1FFAR1ITGB1 | |
| SCHEMBL687907 | 0.94 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EALDH1A1FFAR1ITGB1 | |
| SCHEMBL687970 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EALDH1A1FFAR1PTGER3 | |
| SCHEMBL27741947 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EALDH1A1FFAR1PTGER3 | |
| SCHEMBL693144 | 0.94 | KDM4E (0.37) | SMN1; SMN2KDM4EALDH1A1FFAR1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | claimed |
| EP-3615087-B1 | TARGETING NANOPARTICLES | Texas Childrens Hospital (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11312685-B2 | Targeting nanoparticles | TEXAS HEART INSTITUTE (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210393811-A1 | Imaging Agents and Methods of Use | TEXAS HEART INSTITUTE | 2021-12-23 | — | — | US | disclosed |
| US-20210188774-A1 | Targeting Nanoparticles | TEXAS CHILDREN'S HOSPITAL | 2021-06-24 | — | — | US | disclosed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188774-A1 | Targeting Nanoparticles | PHOSPHO1, CD47, ITGB3 | SMN1; SMN2 1093/4885KDM4E 1682/4885ALDH1A1 2701/4885 |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | SMN1; SMN2 2958/4885KDM4E 2631/4885ALDH1A1 53/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | SMN1; SMN2 2960/4885KDM4E 3292/4885ALDH1A1 57/4885 |
| US-11312685-B2 | Targeting nanoparticles | PHOSPHO1, CD47, ITGB3 | SMN1; SMN2 1093/4885KDM4E 1682/4885ALDH1A1 2701/4885 |
| US-20210393811-A1 | Imaging Agents and Methods of Use | ITGA1, ITGA4, CD47 | SMN1; SMN2 1183/4885KDM4E 1047/4885ALDH1A1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.